Moderate alcohol intake has no impact on acute and chronic progressive anti-thy1 glomerulonephritis.
Moderate alcohol consumption has shown beneficial effects in experimental and human cardiovascular disease. With the use of rat models of acute and chronic progressive anti-thy1 glomerulonephritis (GN), we tested the hypothesis that moderate alcohol intake is protective in renal fibrotic disease. In acute anti-thy1 GN, untreated nephritic rats showed marked mesangial cell lysis and induced nitric oxide production at day 1 and high proteinuria, glomerular matrix accumulation, and transforming growth factor (TGF)-beta(1), fibronectin, and plasminogen activator inhibitor (PAI)-1 expression at day 7 after disease induction, respectively. In animals 15 wk after induction of chronic progressive anti-thy1 GN, disease was characterized by significantly reduced renal function, persisting albuminuria as well as increased glomerular and tubulointerstitial matrix expansion, TGF-beta(1), fibronectin, and PAI-1 protein expression. In both anti-thy1 GN models, an ethanol intake of approximately 2 ml per day and animal was achieved, however, disease severity was not significantly altered by moderate alcohol consumption in any of the protocols. In conclusion, moderate alcohol intake does not influence renal matrix protein production and accumulation in acute and chronic progressive anti-thy1 glomerulofibrosis. The study suggests that, in contrast to cardiovascular disorders, moderate alcohol consumption might not provide specific protection in renal fibrotic disease.
Peters
Harm
H
Division of Nephrology, Charité, Campus Mitte, Humboldt-University, D-10098 Berlin, Germany. Harm.Peters@charite.de
Martini
Sebastian
S
Woydt
Raiko
R
Rückert
Matthias
M
Shimizu
Fuijo
F
Kawachi
Hiroshi
H
Liefeldt
Lutz
L
Krämer
Stephanie
S
Neumayer
Hans-H
HH
D000208:Acute Disease; D000428:Alcohol Drinking; D000818:Animals; D001835:Body Weight; D002908:Chronic Disease; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D000431:Ethanol / Q000008:administration & dosage; D005921:Glomerulonephritis / Q000276:immunology* / Q000473:pathology / Q000503:physiopathology*; D007668:Kidney / Q000473:pathology; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D018800:Thy-1 Antigens / Q000276:immunology*
D018800:Thy-1 Antigens; D000431:Ethanol